Get in-depth discussions on the latest in GI and hepatology, endoscopy and practice management when you attend one or more of the optional Friday courses. Four courses are offered: two, half-day courses, GI Pathology and Imaging Course and What’s New in GI Pharmacology Course; and two, full-day courses, Practice Management Course and the WGO-ASGE Endoscopy Course.
Attending the Postgraduate Course? Register for GI Pathology and Imaging and What’s New in GI Pharmacology and save up to 10 percent! The GI Pathology and Imaging Course and What’s New in GI Pharmacology Course, and the Postgraduate Course make up the Three-day Clinical Review, your comprehensive clinical update.
Course Directors: Brooks D. Cash, MD, FACG, and William D. Chey, MD, FACG
Experts define and describe the use and management of new pharmacological therapies as well as updates in current pharmacological treatment options for a variety of GI disorders during the What’s New in GI Pharmacology Course.
Part of the Three-day Clinical Review—Save up to 10% when you register for the Three-day Clinical Review!
|Friday, October 5, 2018 | 1:45 pm – 5:15 pm|
|1:45 pm||Welcome and Introductions
Brooks D. Cash, MD, FACG, and William D. Chey, MD, FACG
|1:50 pm||Functional Dyspepsia: Current Pharmacologic Approaches
William D. Chey, MD, FACG
Identify the epidemiology, diagnostic processes, and best practices for the management of functional dyspepsia.
|2:10 pm||Contemporary Review of PPI Therapy: What You and Your Patients Need to Know
Stuart J. Spechler, MD, FACG
Discuss the clinical evidence for the use of PPIs in a variety of clinical scenarios, and review current evidence regarding short- and long-term safety of PPIs.
|2:30 pm||Approach to Symptomatic Diverticular Disease
Lisa L. Strate, MD, MPH, FACG
Describe the various presentations of symptomatic diverticular disease, and review current therapeutic approaches.
|2:50 pm||Antibiotic Prophylaxis for the Gastroenterologist
Michelle A. Anderson, MD
Explain the evidence for and against the application of antibiotic prophylaxis in patients with gastroenterological diseases or undergoing endoscopic procedures.
|3:10 pm||Q & A|
|3:40 pm||Pharmacologic Approach to Chronic Constipation and IBS-C
Brooks D. Cash, MD, FACG
Define current and emerging pharmacologic treatment options for constipation, including chronic idiopathic constipation, opioid-induced constipation, and IBS-C.
|4:00 pm||Medical Management of Fatty Liver Disease
Phillip K. Henderson, DO
Discuss the issues and interventions currently available for the management of patients with fatty liver disease, with a focus on available pharmacologic approaches.
|4:20 pm||Chemoprevention for Gastrointestinal Malignancies
John M. Inadomi, MD, FACG
Identify the evidence for and against chemoprevention for malignancies of the gastrointestinal tract and provide recommendations for appropriate use.
|4:40 pm||Personalized IBD Management: Best Practices for Therapeutic Drug Monitoring and for Managing Treatment Failures
David T. Rubin, MD, FACG
Outline therapeutic drug monitoring in IBD patients, and how to optimize immunosuppressive drug therapy with regard to adjusting therapy in class or switching classes of biologics.
|5:00 pm||Q & A|
|5:15 pm||What's New in GI Pharmacology Course Adjourns|